Open-label Extension Study of Brazikumab in Ulcerative Colitis

NCT04277546 | Terminated Phase 2 FDA Drug

• 3 other identifiers: D5272C00002#3151-202-0082021-001644-10
• Study Type: interventional
• Target: 57
• Locations: 11 countries
• Sites: 36

Brief Summary

The purpose of this OLE Study D5272C00002 (Legacy #3151-202-008) is to permit participants who previously enrolled in the double-blind Study D5272C00001 (Legacy #3151-201-008) to receive brazikumab, allowing for long-term observation of safety and efficacy in these participants treated with brazikumab. There are no formal hypotheses to be tested. Safety and efficacy data obtained in this study will be included in regulatory product submissions as appropriate.

Conditions

Ulcerative Colitis

Outcome Measures

Primary Outcomes (5)

• Number and percentage of patients with adverse events

  Number and percentage of patients with reported adverse events.

  Through week 70

• Percentage of patients with potentially clinically significant changes in laboratory values

  Percentage of patients with potentially clinically significant changes in hematology, clinical chemistry, urinalysis.

  Through week 70

• Percentage of patients with potentially clinically significant changes in vital signs

  Percentage of patients with potentially clinically significant changes in systolic and diastolic blood pressure, and pulse rate.

  Through week 70

• Percentage of patients with potentially clinically significant changes in physical exams

  Percentage of patients with potentially clinically significant changes in full physical exams.

  Through week 70

• Percentage of patients with potentially clinically significant changes in ECGs

  Percentage of patients with potentially clinically significant changes in 12-lead ECG recordings.

  Through week 70

Study Arms (2)

Brazikumab Maintenance Dose

EXPERIMENTAL

Administer at 4-week intervals through Week 52 Participants who receive IV induction dosing will be administered brazikumab SC at 4-week intervals starting Week 12 through Week 52

Drug: Brazikumab Maintenance Dose

Brazikumab Induction Dose

EXPERIMENTAL

Administer at Week 0, Week 4, and Week 8

Drug: Brazikumab Induction Dose

Interventions

Brazikumab Maintenance Dose DRUG

Completers in the lead-in study D5272C00001 (Legacy #3151-201-008) will receive a maintenance dose of brazikumab administered subcutaneously every 4 weeks up to Week 52 (Group A). The SC dose of brazikumab will be administered to all responders/completers in the lead-in study regardless of the prior treatment administered.

Brazikumab Maintenance Dose

Brazikumab Induction Dose DRUG

Participants in the lead-in study D5272C00001 (Legacy #3151-201-008) who have not responded to treatment and have met criteria for rescue treatment are considered inadequate/non-responders (Group B). In these eligible participants, IV induction dosing of brazikumab at Week 0, Week 4, and Week 8 will be administered, followed by brazikumab administered subcutaneously every 4 weeks thereafter (up to Week 52).

Brazikumab Induction Dose

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female participants who: successfully completed or discontinued participation due to lack of efficacy after Week 10 in the lead-in Study D5272C00001 (Legacy #3151-201-008). AND Meets 1 of the following criteria for successful completion or early termination from Study D5272C00001 (Legacy #3151-201-008):
• Participant completed Study D5272C00001 (Legacy #3151-201-008), received scheduled study interventions, completed scheduled visits, and completed Week 54 assessments.
• Participant discontinued participation due to lack of efficacy after Week 10 in Study D5272C00001 (Legacy #3151-201-008), received scheduled study interventions, and completed Early Termination Visit assessments.
• Deleted Eligibility as part of Amendment 2 1.03. Deleted Eligibility as part of Amendment 3 1.04. Deleted eligibility as part of Amendment 2 2.01. Male participants willing to minimize the risk of inducing pregnancy for the duration of the clinical study and follow-up period. Nonsterilized men who are sexually active with a female partner of childbearing potential should use condom during treatment and for 18 weeks after the last dose of study intervention, must comply with the methods of contraception described in Criterion 2.02 below, and must not donate or bank sperm for fertilization purpose for the same time period.
• Female participants of childbearing potential must have a negative urine pregnancy test prior to administration of study intervention and must agree to use a highly effective method of birth control (confirmed by the investigator) from signing the ICF throughout the study duration and for at least 18 weeks after last dose of study intervention 2.03. Women not of childbearing potential are defined as women who are either permanently sterilized (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), or who are postmenopausal.
• Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
• Written informed consent from the participant has been obtained prior to any study related procedures.
• Written documentation has been obtained in accordance with the relevant country and local privacy requirements, where applicable (eg, Written Authorization for Use and Release of Health and Research Study Information \[US sites\] and written Data Protection consent \[EU sites\]).
• Demonstration of adequate compliance with the study procedures in Study D5272C00001 (Legacy #3151-201-008), in the opinion of the investigator and/or sponsor.
• Willingness and ability to attend all study visits, comply with the study procedures, and be able to complete the study period.
• Participant must be 18 to 80 years of age inclusive, at the time of signing the ICF.

You may not qualify if:

• Any participant with an unresolved AE from the lead-in study that, in the investigator's opinion, would limit the participant's ability to participate in or complete this study. Any unresolved AE related to an infection will require further discussion with the study physician/designee prior to enrollment.
• Current diagnosis of fulminant colitis, CD or indeterminate colitis, presence of a fistula consistent with CD, primary sclerosing cholangitis, celiac disease, or toxic megacolon. Bile acid malabsorption and other conditions that may potentially confound assessments must be treated prior to baseline.
• Organ or cell-based transplantation with the exception of corneal transplant.
• Any other condition or finding that, in the investigator's or sponsor's opinion, would either confound proper interpretation of the study or expose a participant to unacceptable risk.
• Evidence of intestinal epithelial dysplasia on endoscopy, and this is confirmed on biopsy, the participant must be excluded.
• Any diagnosis of malignancy that requires discontinuation of study intervention from lead-in study.
• Any new diagnosis of malignancy after completion of the lead-in study. d) Carcinoma in situ of the cervix, with apparent successful curative therapy within 12 months prior to Week 0.
• Participant meets criteria for discontinuation of study intervention during prior lead-in study.
• Prolonged QTcF interval or conditions leading to additional risk for QT prolongation. Participants with electrolyte abnormalities such as hypokalemia and hypomagnesemia that would increase the risk of QT prolongation are to be corrected prior to enrollment.
• Clinically significant kidney disease including but not limited to:
• (a) Chronic kidney disease with an estimated glomerular filtration rate of less than 30 ml/min calculated by Modification of Diet in Renal Disease equation, asapplicable, by the central laboratory at screening are excluded.
• Participant requires additional immunosuppressive therapy (aside from permitted concomitant medication in the protocol), biological treatment or prohibited treatment 2.02. Deleted eligibility as part of Amendment 2 2.03. Participant received a prohibited medication during participation in the D5272C00001 (Legacy #3151-201-008) study.
• Participant received a Bacille Calmette-Guérin vaccination within 12 months of Week 0 or any other live vaccine \< 4 weeks prior to Week 0, or is planning to receive any such vaccine over the course of the study.
• Participant has received an investigational product after discontinuation from Study D5272C00001 (Legacy #3151-201-008) and prior to enrolling in this study or participant is planning to receive an investigational drug (other than study intervention) or investigational device at any time during Study D5272C00002 (Legacy #3151-202-008).
• Participant who discontinued participation due to lack of efficacy after Week 10 in Study D5272C00001 and did not receive all 3 IV infusions of study interventions scheduled for Week 0 (Day 1), Week 2 (Day 15), and Week 6 (Day 43), and SC at Week 10 (Day 71) in accordance with the protocol for Study D5272C00001.

Sponsors & Collaborators

• AstraZeneca: lead

Study Sites (36)

Research Site

Chula Vista, California, 91911, United States

Location

Research Site

Lancaster, California, 93534, United States

Location

Research Site

Colorado Springs, Colorado, 80907, United States

Location

Research Site

Lakeland, Florida, 33813, United States

Location

Research Site

Miami, Florida, 33165, United States

Location

Research Site

Miami Lakes, Florida, 33016, United States

Location

Research Site

Evansville, Indiana, 47715, United States

Location

Research Site

Beachwood, Ohio, 44122, United States

Location

Research Site

Oklahoma City, Oklahoma, 73112, United States

Location

Research Site

Humble, Texas, 77346, United States

Location

Research Site

České Budějovice, 370 01, Czechia

Location

Research Site

Ostrava, 702 00, Czechia

Location

Research Site

Hamburg, 20251, Germany

Location

Research Site

Kiel, 24105, Germany

Location

Research Site

Ulm, 89081, Germany

Location

Research Site

Haifa, 3109601, Israel

Location

Research Site

Jerusalem, 9103102, Israel

Location

Research Site

Milan, 20132, Italy

Location

Research Site

Rho, 20017, Italy

Location

Research Site

Roma, 00168, Italy

Location

Research Site

Kasama-shi, 309-1793, Japan

Location

Research Site

Kashiwa-shi, 277-0871, Japan

Location

Research Site

Minatoku, 108-8642, Japan

Location

Research Site

Krakow, 31-513, Poland

Location

Research Site

Rzeszów, 35-302, Poland

Location

Research Site

Sopot, 81-756, Poland

Location

Research Site

Torun, 87-100, Poland

Location

Research Site

Warsaw, 00-635, Poland

Location

Research Site

Warsaw, 03-580, Poland

Location

Research Site

San Juan, 00927, Puerto Rico

Location

Research Site

Cape Town, 7500, South Africa

Location

Research Site

Cape Town, 7708, South Africa

Location

Research Site

Plumstead, 7800, South Africa

Location

Research Site

Wŏnju, 26426, South Korea

Location

Research Site

Taichung, 40447, Taiwan

Location

Research Site

Taipei, 10002, Taiwan

Location

MeSH Terms

Conditions

Colitis, Ulcerative

Condition Hierarchy (Ancestors)

Colitis; Gastroenteritis; Gastrointestinal Diseases; Digestive System Diseases; Inflammatory Bowel Diseases; Colonic Diseases; Intestinal Diseases

Study Officials

• Kathy Bohannon

  AstraZeneca

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 18, 2020
• First Posted: February 20, 2020
• Study Start: March 3, 2020
• Primary Completion: October 10, 2023
• Study Completion: October 10, 2023
• Last Updated: November 9, 2023

Record last verified: 2023-10

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP
• Time Frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
• Access Criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Locations

KR (1); IT (3); CZ (2); PL (6); PR (1); US (10); IL (2); ZA (3); DE (3); TW (2); JP (3)